The Land Rover Burghley Horse Trials has announced a £15,000 bursary to the Animal Health Trust. The bursary will be used to help fund the development of a rapid result blood test to identify horses infected with Strangles.
The AHT has already developed a test that can detect the disease, however the result is not known for 48 hours. The aim of the new research is to develop the test to produce a result within 10 minutes. The test, which is being developed in conjunction with Forsite Diagnostics Ltd, will be a useful tool for disease screening at sales and competitions.
"As an independent charity we receive no government funding and this bursary is extremely important to us and we are delighted to be working in partnership with The Land Rover Burghley Horse Trials on this specific project," said Dr Richard Newton of the AHT who is carrying out the research in partnership with Professor Andrew Waller. "Without this vital funding to carry out the painstaking work that will give us the confidence to launch the test, it will remain no more than a theoretical possibility."
The Bursary will be presented at this year's Land Rover Burghley Horse Trials (1- 4 September 2011) - in recognition of the 50th Anniversary of the event.
"With increasing horse movement, not only world-wide but closer to home between competitions and livery yards, preventing the spread of disease is an increasingly important challenge facing the horse world," said Elizabeth Inman Director of the Trials. "We are delighted to be able to play a part in this challenge and hope that this anniversary bursary will help to fast-track this new test out of the laboratory and into the field and thereby help reduce the spread of what is a horrible disease for horses and owners."
The organisers have invited veterinary experts to share their knowledge and expertise in gastroscopy, sinoscopy and upper respiratory tract (URT) endoscopy, using cadaver heads and state of the art models, during daily practical sessions.
Practical sessions will guide delegates through the most commonly used equine endoscopy procedures, including how to perform gastroscopy, how to perform upper respiratory tract endoscopy and exploration of the guttural pouches and how to get the most out of sinoscopy.
Each session will include a review of the anatomy involved and helpful tips from experts Jonathan Anderson, Tim Barnett, Imogen Comyn, Ollie Crowe, Sarah Mack, Patrick Pollock, Alex Rafferty, Richard Reardon, Neil Townsend, Sophie Wilford and Tom Witte.
The gastroscopy practical will make use of a custom synthetic model of a horse’s oesophagus and stomach, uniquely developed by BEVA, Burtons and DeLegge Medical Design in the USA. The URT endoscopy practical will utilise cadaver heads on stands so delegates can look at laryngeal components, sinus drainage angle, ethmoids, guttural pouch ostia and can then scope/ pass foley catheters/chambers catheters in to guttural pouches. Pre-prepared cadaver heads will also be used for the sinoscopy practicals. Frontal sinus trephine holes will allow a scope to be inserted and one side will be broken through the maxillary septal (ventral conchal) bulla so delegates can compare the differences in anatomy.
At the end of each demonstration Burtons, who have sponsored the event and supplied the endoscopic equipment, will be providing advice on how to clean and maintain scopes properly.
Mark Bowen, President of BEVA, said: "BEVA is committed to providing innovative and practical CPD through its entire CPD programme, including congress and these practical sessions showcase the excellent and varied education provided to members. At a time when the RCVS are considering the value of certain types of CPD in improving professional competence, BEVA is committed to leading the field and challenging perceptions of what a modern conference can be."
The practical sessions will run on all three days of Congress on the balcony above the exhibition hall. Each session will comprise a demonstration and then three practical slots, each for a maximum of ten delegates. Places can be secured on a first come first served basis by signing up on the day.
Visit www.beva.org.uk to find out more and to sign up.
Merial Animal Health has announced that the duration of immunity for the tetanus component of Proteqflu-Te has been extended to 2 years.
Merial's Veterinary Technical Manager Kevin Whelan said: "This is a welcome new addition to the label claims for this advanced vaccine, which is the only equine flu vaccine in the UK to contain a recently updated influenza virus strain. The updated strain, innovative canarypox vector technology and now the extended tetanus duration of immunity claim make the vaccine an excellent choice for vets in the UK"
Merial says Proteqflu-Te can now be used on an alternate year basis in combination with the company's other flu vaccine, Proteqflu, which does not contain tetanus toxoid. The one year duration of immunity for the influenza component remains unchanged.
Please contact your local Merial Representative or the Merial Technical Support line on 0870 6000 123 for further information.
Strangvac has been in development for over 25 years and Dechra says it's the first and only intramuscular vaccine to help protect against strangles.
Strangvac contains recombinant proteins CCE, Eq85 and IdeE from Streptococcus equi and has DIVA (Differentiating Infected from Vaccinated Animals) capability.
The vaccine contains no live bacteria or bacterial DNA, so will not trigger positive culture or PCR tests.
In trials the new vaccine protected more than 94% of horses1.
Dechra says it reduces the clinical signs of strangles including a high temperature, coughing, inappetence, difficulty swallowing and changes in demeanour, while also reducing the number of lymph node abscesses.
Strangvac can be given to foals from five months of age and two injections should be given at a four-week interval.
Horses at high risk of Streptococcus equi infection, such as those in livery, should be revaccinated after two months.
Based on measured antibody titres, immunological memory was found in horses following repeated vaccination six months after primary vaccination.
Dr Andrew Waller, chief scientific officer at Intervacc AB, the company that developed the vaccine, said: “Strangvac is a ground-breaking new vaccine which, alongside good stable management and biosecurity procedures, can play a really important role in improving herd immunity and reducing the number of strangles cases in the equine population, thereby preventing major economic loss to the equestrian industry.”
https://www.dechra.co.uk/equine/vaccines
The first steps have begun to find Petplan and The Veterinary Business Journal's Practice Manager of the Year for 2012.
Nominations are now being sought for the most accomplished UK practice managers and recommendations are welcome from any member of the veterinary team.
Three finalists will be chosen and the winner announced at the annual Petplan Veterinary Awards in April 2012.
Robin Fearon, editor of the Veterinary Business Journal, said: "It is a distinct pleasure to launch the awards programme each year knowing that at the end of it we will be able to announce another winning practice manager.
"These awards are so important in promoting the role and highlighting the crucial part that managers play in practice strategy and success - we can't wait to see your nominations."
Judges will assess candidates' applications and choose the three finalists based on their competency in areas such as staff development, financial strategy and marketing initiative.
Last year's winner Denise Coston is practice manager at Castle Veterinary Surgeons in County Durham. She said: "Winning this award has meant a lot to me because it makes you feel valued. I would say to anyone thinking of nominating their practice manager: 'just do it'.
"The role of practice manager varies in each practice and can be hard to quantify with specific measures, but it means a lot to celebrate someone getting it right. It is an excellent way to promote the role of practice manager and it is great to get recognition alongside vets and nurses."
This award is supported by the Society of Practising Veterinary Surgeons and the Veterinary Practice Management Association.
As well as a plaque commemorating their achievements, the winner will once more receive one year's free membership to the VPMA.
Nominations for this year's award close on 10 February 2012. Application packs are available from: Jackie Morrison, The Veterinary Business Journal, Olympus House, Werrington Centre, Peterborough PE4 6NA, or e-mail jackiemorrison@vbd.uk.com.
Alternatively visit www.vetsonline.com/ to download yours direct.
Pfizer Animal Health has launched PrintRoom, an online printing service to help equine practices deliver high quality communications to their clients, to support the company's Equip range of equine vaccines.
PrintRoom can be used to produce customised vaccination reminder cards, invitations, letterheads, stable name sheets, and more.
You can choose from a palette of designs, images and colours and can also upload your own logos and images to tailor your client communications to your preferred style.
PrintRoom has a MailMerge option to pre-address all your mailings and you can pay for postage and set the date of despatch online, to help ensure boosters are administered on time and passports stay up to date.
Paul Blanc, Equine Brand manager at Pfizer said: "Good communication with your clients plays a vital role in maintaining vaccination compliance and retaining and gaining business. Our print room service makes it easy to produce a broad range of customised practice marketing materials to a very professional standard that stand out from the crowd."
For further information visit http://www.pfizerprintroom.com/, call 0845 6027439 or contact your Pfizer Account Manager.
An international group of scientists has published new results that herald a breakthrough in finding a vaccine against the most commonly diagnosed infectious disease of horses, strangles.
UK experts from the Animal Health Trust collaborated with scientists from the Swedish University of Agricultural Sciences (SLU), the Karonlinska Institutet Medical University and Intervacc AB, on the project - the results of which could benefit humans as well as animals.
Professor Andrew Waller, Head of Bacteriology at the AHT, said: "We have been working towards developing a vaccine for 7 years, and finally it seems as if all the hard work is paying off. We've already developed better ways of diagnosing exposure to the infection, and now, with the success of creating a safe and effective vaccine, it looks as if we're finally bringing together the tools necessary to eradicate this terrible disease."
The vaccine consists of seven different Streptococcus proteins and results from early tests published in PLoS Pathogens have been incredibly positive showing a high level of protection and no side effects. It is hoped that the strangles vaccine could be commercially available in the near future.
Streptococcus equi, the bacterium that causes strangles, shares 80 per cent identity with Streptococcus pyogenes - the leading cause of bacterial pharyngitis, tonsillitis and rheumatic fever in humans, which kills thousands of people each year. Scientists hope that the knowledge gained through developing the strangles vaccine will also help in developing vaccines to combat these human conditions.
Research leader, Professor Bengt Guss of SLU, said: "This is a most exciting project, where research is generating new applications and knowledge that can be used to develop vaccines against these important bacteria. This is particularly important considering the increased number of infectious diseases caused by antibiotic-resistant bacteria."
The vaccine development work was only made possible thanks to information from the Streptococcus equi genome sequencing project funded by The Horse Trust.
The Horse Trust's Chief Executive Brigadier Paul Jepson, said: "We are absolutely delighted that by pulling apart the genome of this plague of the horse world scientists have generated a truly safe and effective strangles vaccine. That this work could also benefit other animal and human health is beyond our wildest hopes."
Full text of the research findings can be found in PLoS Pathogens online at http://www.plospathogens.org/article/info%3Adoi%2F10.1371%2Fjournal.ppat.1000584
A new study1 published in the Equine Veterinary Journal's (EVJ) special American Association of Equine Practitioners supplement has concluded that maggots can play an integral role in modern veterinary care for a variety of wounds in horses.
The study assessed the efficacy of maggot debridement therapy in a diversity of equine lesions and found that the method was beneficial in 93% of cases.
Maggots have been used for the treatment of wounds for hundreds of years. Freshly emerged, germ-free larvae of the common green bottle fly are usually used for the purpose. Their wound-healing action is attributed to a debridement effect, an antiseptic effect, a direct effect on cytokine and cell proliferation involved in wound healing and breakdown of biofilm formation. Maggots also destroy and digest bacteria and may also be beneficial in the fight against multi-drug-resistant bacteria such as MRSA.
The study involved the retrospective analysis of 41 horses with various lesions including foot injury, limb laceration, soft tissue abscesses and musculoskeletal infection. Depending on the type, size and location of the wound the maggots were applied either in direct or indirect contact. In some cases a second maggot application was necessary to reach the desired level of healing. Debridement, disinfection and healing occurred in all but three cases, in less than a week. Of the three that did not respond two were complicated by the presence of tumours and one by pre-existing damage to the underlying bone.
Olivier Lepage of the University of Lyon, who led the study, said: "These results show that maggot debridement therapy potentially has an integral place in modern veterinary wound care. It can be used to treat many types of lesions, although not those involving tumours or bone sequestration. Associated high costs present a limiting factor but maggot debridement therapy should certainly be considered for lesions that fail to respond to conventional methods."
Professor Celia Marr, Editor of the EVJ, said: "Horses often suffer from non-healing wounds, particularly in the limbs where the skin is under continuous movement and there is very little subcutaneous tissue. Although at first glance this study might seem counter-intuitive and we might think of maggots as being the last thing one would want on a clean wound, it shows that maggots can be an effective way to clear damaged tissue and this is an important adjunctive approach in equine wound management."
1The use of maggot debridement therapy in 41 equids OM Lepage, A Doumbia, MF Perron-Lepage and M Gangl. EVJ ISSN 0425-1644 DOI: 10.1111/j.2042-3306.2012.00609.x
The study is published by Wiley-Blackwell and can be accessed at http://onlinelibrary.wiley.com/doi/10.1111/j.2042-3306.2012.00609.x/abstract
From early 2025, all vets, nurses and technicians will be required to wear a hard hat in the vicinity of a horse, pony or donkey – whether in practice, on a yard, or at a client’s premises.
It follows a three-year research project collaborating with the University of Liverpool which revealed that 90% of veterinary clinicians have experienced an injury during their career.
It is hoped that the move will reduce injuries to the head – one of the most common traumas to be suffered by equine vets identified by the research, usually sustained when examining distal limbs. CVS says that in the US, equine vets sustain on average eight serious injuries during their career, making it the second highest profession for non-fatal injuries.
The University of Liverpool research found that over 25% of equine vet injuries have led to hospital attendance. Dr. John Tulloch, Lecturer and European Specialist in Veterinary Public Health at the University of Liverpool, who led the research, said: “Vet visits are not an ‘everyday activity’ for a horse.
"As a result, many horses will be on heightened alert, and some may be more prone to unpredictable behaviour. “Vets are often in a vulnerable situation when examining a horse.
"And it’s difficult to pick up on a horses’ signals, especially when examining areas such as distal limbs. “Our research found that many injuries happen when a horse kicks or pushes a person over and the person’s head makes impact with the ground.
"So, wearing a hard hat will be a big step towards preventing traumatic head injuries if this were to happen.” Sophie Ignarski, Equine Director at CVS said: “All of our clinicians are at risk in their day-to-day work – whether they are newly qualified or very experienced.
"Other colleagues including nurses, vet techs and patient care assistants are similarly vulnerable. “We decided to make wearing of hard hats mandatory in order to protect all of our colleagues and minimise the potential risk of head injury, understanding it can never be fully eliminated.
"We recognise that this policy shift represents a degree of change but hope that it serves to further support and progress the equine veterinary industry more widely. “Our policy is evidence-based, utilising three years of rigorous research, and we will continue our efforts in the future to grow our knowledge and understanding of this important area.
"By doing so, we join other industries – such as construction – who have already adopted similar changes to the extent they are now established in their culture.”
https://www.sciencedirect.com/science/article/pii/S0167587725001266
According to the company, information on best worming strategies for foals and yearlings remains largely anecdotal, making it difficult to develop a clear plan for this age group. Zoetis veterinary surgeon Wendy Talbot has therefore reviewed the recent literature to develop an eight-point plan.
Explaining the guidance, Wendy writes:
Foals and yearlings are usually more susceptible to worms than are adult horses because they have had little chance to develop any immunity. They are more vulnerable to related diseases and tend to have higher egg shedding, which increases the risk of infection. The main parasitic culprits in the UK for foals less than six months of age are large roundworms (ascarids). In older foals and weanlings, small and large strongyles, tapeworms (and pinworms) are the main considerations.1 Yearlings may also have a second wave of large roundworm infection at 8-10 months of age.2 Any control strategy will need to take into account the individual circumstances such as stocking density, pasture management and previous disease history.
Guidelines for parasite control in foals suggest a first treatment with fenbendazole at 2-3 months of age, targeting large roundworm, followed by another treatment at 5-6 months. Alternatively, pyrantel may be considered for these doses; however, there may be resistance in some areas and foals with large adult ascarid burdens may be at higher risk of intestinal rupture when this drug is used.4 At weaning (approximately six months of age), it is advisable to perform a faecal worm egg count (FWEC) to determine if treatment for strongyles is also required; the macrocyclic lactone anthelmintics (ivermectin or moxidectin) are expected to have the highest efficacy. At 9 and 12 months of age treatment for stronglyes and a larvicidal dose for encysted stages of small strongyles (moxidectin or a 5 day course of fenbendazole) are indicated. A tapeworm treatment should be included with one of these doses.2,3
For yearlings, two methods have recently been proposed for worm control: the first involves using faecal worm egg counts (FWECs) at more frequent intervals than for adults to guide dosing for strongyles in the grazing season.1 The second suggests three baseline treatments targeting strongyles in spring, summer and late autumn, with FWECs in between to identify and treat any still shedding high numbers of eggs, up to a maximum of six treatments per year.2 Macrocyclic lactones have the highest expected efficacy against small strongyles and should form the basis of treatments; however, pyrantel can be considered for some treatments where it has been shown to have continued efficacy. Both strategies include a larvcidal treatment for encysted small redworm combined with testing or treating for tapeworm in late autumn. The inclusion of one or two doses of a macrocyclic lactone each year (usually already used for small strongyle control) should be sufficient to prevent large strongyle related disease.3
The wide differences in the circumstances of foals and yearlings, together with geographical variations in resistance patterns and a lack of consensus on best practice in this group means it is not possible to define a single approach to a worming plan. An important point to note is that FWECs may give surprising results because higher counts are generally seen in youngstock.
Eight ways to keep clients' youngstock worms controlled:
For further information on worming together with some equine specific CPD visit: https://blog.vetsupportplus.com/
The new packaging uses fewer plastic components and a new cardboard box.
Sabrina Jordan, Virbac’s Equine Product Manager said: "The new cardboard component is a substantial step forward making the new packaging more environmentally friendly."
She added: "This new Equimax packaging has a fresh new look and is now available at wholesalers."
David says that whilst he was out there, he was told about attacks by Russian forces on stables in Bucha, Irpin and other equestrian premises north of Kyiv.
Ukraine vet Anatoly Levitsky who is working in Kyiv, said: “Not very big horse club was not far from Borodianka and owners were using their horses for hippotherapy of children with different pathologies.
"When war started, the lady who owned the stable and her child emigrated to Poland and her husband was conscripted into Ukrainian army.
"When Russian bandits in army uniform came to the village, they set fire to the stable and started shooting the horses that tried to escape.”
“Some horses ran away, others were wounded, and some were burned down.
"After the building was burned, Russian soldiers went away and horses that escaped were wandering around the village and trying to find the feed.
"Step by step, people living in the village collected the horses and keep one or two horses in their yards.”
David said: “It is hard to understand what could motivate anyone to perform these deliberate acts of cruelty.
"Random shootings, stabbings and burnings are widely reported and pictured on social media, we have no idea how many horses are dead and how many injured, but it has to be a significant number.
“Some of the lorry drivers I have met coming out have been shot at, shelled and beaten up, evacuating surviving horses.
"They are taking risks that we would consider totally unacceptable to move animals out and supplies in.
"I have nothing but admiration for the bravery of the Ukrainian people.”
“Ever conscious that there is an equal humanitarian need you feel very small and rather cowardly that you aren’t permitted to go into Ukraine to help the people and animals that require treatment.”
The British Equine Veterinary Association and American Association of Equine Practitioners are working together to support vets in Ukraine.
They say that they are not allowed to provide direct practical help, but they are doing what they can to get veterinary and humanitarian supplies to the vets they are in contact with.
They are also working to establish safe stables in the West of Ukraine to get horses and their owners away from likely areas of combat in the East.
Previously people have had no option but to turn horses into the woods prior to fleeing or they have stayed to look after their animals despite the risks to themselves.
BEVA, in association with the British Equestrians for Ukraine Fund, is calling for urgent support to help fund veterinary treatment, supplies and the safe relocation of Ukraine’s endangered horses.
To do this they need your urgent support. To make a donation visit https://www.worldhorsewelfare.org/support-us/appeals/british-equestrians-for-ukraine-fund.
To find out more you can listen to a podcast from David Rendle here https://beva.podbean.com/e/bevapod-episode-13/
Photo: Stabling reportedly burned down by Russian soldiers
Ceva Animal Health has highlighted a new study which revealed that the use of the opioid buprenorphine, the active ingredient in Vetergesic, before equine elective general anaesthesia and surgery resulted in better post-operative analgesia than butorphanol, without causing further physiological disruption than is normally expected of general anaesthesia in horses.
The prospective, randomised and blinded multicentre study, conducted by Dr Polly Taylor VetMB MA PhD DVA DipECVAA MRCA MRCVS, an RCVS Specialist in Veterinary Anaesthesia, compared the degree of post-operative pain and physiological variables in horses following premedication with either buprenorphine or butorphanol in a general clinical setting. The study included 89 healthy adult horses from six UK equine veterinary clinics admitted for routine elective surgical procedures.
Ceva says that butorphanol is often used in equine procedures due to familiarity and its value for enhancing alpha2-induced sedation, but that it is probably the least effective opioid as an analgesic. There is also a common perception that butorphanol has less impact on locomotor stimulation and depression of intestinal motility than other opioids. This is likely to have contributed to the almost exclusive use of NSAIDs to manage pain in the post-operative period.
To view the full study, visit http://onlinelibrary.wiley.com/doi/10.1111/evj.12442/abstract. For details on Ceva's analgesic product range, email analgesics-group@ceva.com or call 01494 781510.
Ridgeway Research Ltd has a surplus supply of short-dated Target IgG kits on special offer.
The kits are to test for passive transfer to foals via colostrum. Each kit contains 20 tests and normally costs £74. They have been reduced to £20 to clear. The use by date is end February 2010.
If you are interested, please email jo@ridgewayresearch.co.uk, or ring 01594 530809 for further information.
Veterinary practices are being urged to raise awareness of summer skin conditions, such as sweet itch, following research carried out by Elanco Companion Animal Health, distributor of Cavalesse, which revealed that vets only tend to be consulted after horse owners have tried to manage the condition themselves (73%), or if the clinical signs have become severe (67%), potentially leading to major welfare implications.
According to the research, this is despite the fact that over half (55%) of owners of a horse with sweet itch showed concern that their horse will suffer, and nearly half being stressed about the way the condition will affect it (47%). While many horse owners are fairly knowledgeable about the causes of sweet itch and its clinical signs, over a quarter of respondents (26%) did not start managing the condition before the midge season in the spring, which may make managing the condition more frustrating. Nearly a third (31%) stated that they had to curtail their activities with their horse due to welfare, aesthetic and behavioural issues, such as head shaking, rubbing, unpredictability and aggression.
Ed Whittle, technical consultant at Elanco Companion Animal Health said: "86% of those questioned considered sweet itch to be a very serious welfare issue if left untreated, with the worst aspects of the condition being the suffering and distress caused by the constant irritation which affects the quality of life of the horse. Over half (55%) felt that sweet itch had adversely affected the behaviour of their horse, making them difficult to handle or ride. Veterinary practices should be proactively talking to their clients about summer skin conditions such as sweet itch to help alleviate the suffering and distress caused by this frustrating disease."
Elanco says it will be joining forces with the British Horse Society (BHS), The Blue Cross, The Horse Trust, Redwings Horse Sanctuary and World Horse Welfare (WHW) to raise awareness of summer skin conditions, such as sweet itch, during Sweet Itch Awareness Month (SIAM) in March. The campaign will highlight the preventative measures that should be carried out to help alleviate sweet itch and the importance of management of the condition before the start of the midge season in the spring.
Lee Hackett, head of welfare at the BHS, said: "The results of this survey show just how important raising awareness of sweet itch is. All of us, whether we are welfare organisations or vets, need to play our part in educating owners about sweet itch in the hope that they will seek expert advice at an earlier stage and reduce the number of horses that suffer as a result of this condition."
Kerry Taylor, education officer at The Blue Cross, said: "The Blue Cross is pleased to be supporting the sweet itch campaign to raise awareness of the physical and mental impact this condition has on horses. During our May 2011 National Equine Health Survey, skin problems came out the top syndrome affecting horses, and we continue to see many horses coming into our care suffering from sweet itch. Prevention and early treatment is key to managing the potentially debilitating condition."
For further information on sweet itch, Sweet Itch Awareness Month or Cavalesse, please visit http://www.fidavet.com/, or contact Elanco Companion Animal Health, Lilly House, Priestley Road, Basingstoke, RG24 9NL, 01256 353131.
Reference
Sweet itch - effect on horse and owner. Mo Gannon & Associates. Web survey in November 2011. 351 responses - owners who have owned horses with sweet itch in the last two years.
Wiley has announced the joint online publication of a special issue of 22 ophthalmology papers from Equine Veterinary Journal, Equine Veterinary Education and Veterinary Ophthalmology.
Clinical equine ophthalmology: The current state of the art brings together papers on some of the most significant advances in equine clinical ophthalmology into a single issue to make them more readily available to a wider audience. The issue contains information of direct relevance to all sectors of the veterinary profession from general practitioners and specialists to researchers, surgeons and students, covering common diseases, surgical procedures and outcomes.
The new publication was devised and compiled by a panel of guest editors comprising Mary Lassaline, member of the Veterinary Ophthalmology Editorial board and Veterinary Ophthalmologist in the Department of Surgical and Radiological Sciences at UC-Davis School of Veterinary Medicine, California, David A. Wilkie, Editor of Veterinary Ophthalmology and Professor at Veterinary Clinical Sciences Comparative Ophthalmology Ohio State University, Tim Mair, Editor of Equine Veterinary Education based at Bell Equine Veterinary Clinic, Kent and Celia M Marr, Editor of Equine Veterinary Journal, based at Rossdales, Newmarket.Mary Lassaline said: "The goal was to provide broad access to the most current information applicable to every stratum of the equine veterinary profession. Subsequently, a salient feature is that many of the papers included are collaborations between veterinary ophthalmologists with a special interest in horses, equine practitioners with a special interest in ophthalmology, private practitioners and those in academia, and academicians from different institutions."
Subjects covered include seven papers on new approaches to the diagnosis and treatment of ulcerative and non-ulcerative keratitis in the horse. There are three articles on novel approaches to corneal surgery and a further three on corneal neoplasia. Six papers provide valuable data regarding long-term outcomes following surgical intervention for Equine Recurrent Uveitis (ERU), glaucoma, and cataracts. Finally, three articles present new information regarding retinal and orbital disease.
Professor Celia Marr, Editor of the Equine Veterinary Journal said: "The key purpose of the EVJ is to disseminate information to help the enhancement of specialist knowledge at every level of the veterinary profession. By collating the most important and up-to-date ophthalmology research into one easy resource the new special issue does exactly that."The ophthalmology special issue is available free online at: http://bit.ly/1bi0RG0
Hand-mouldable into any shape, Hoof Repair is used to create prosthetic hoof extensions and additions that restore foot integrity.
The company says there is no exothermic reaction when the thermoplastic hardens, which eliminates issues caused by excessive heat and makes the product suitable for treating acute laminitis, cracked hooves and horses that have lost a lot of hoof.
When used with Imprint Structural Adhesive, Hoof Repair forms a bond with hoof wall which can be nailed into and rasped, and will stay in place as hoof grows. Hoof Repair is also suitable for treating foal foot deformities.
The company says Hoof Repair is often used in conjunction with Imprint shoes, which are made of the same low melt, long lasting thermoplastic. It allows extensions to be made to the shoes and together the Imprint system protects and supports the hoof allowing the foot to flex and move freely.
Andrew Poynton, Imprint’s Inventor said: "Hoof Repair forms part of a foot care system that has been developed over 20 years by farriers in association with veterinary surgeons. Hoof Repair assimilates hooves precisely to retain the foot integrity and it is particularly useful for treating acute laminitis and cracked or badly damaged hooves."
Intervet/Schering-Plough Animal Health has announced that it is re-introducing Equilis StrepE, the only strangles vaccine for horses in Europe. The vaccine was voluntarily withdrawn from the market in 2007 for stability reasons.
Equilis StrepE, which has already been relaunched in the Netherlands, is now scheduled to arrive in Italy in September and the United Kingdom in October this year. Further re-launches in European countries are scheduled later in 2010 and beyond.
According to Intervet/Schering-Plough, three years of additional research and development have resulted in several improvements to the vaccine, including a better manufacturing process to ensure that the product maintains its characteristics throughout its shelf-life. A more user-friendly applicator has been developed, which enables the needle to slot into place, thereby making it easier to administer the vaccine.
Equilis StrepE is administered through a submucosal injection in the upper lip of the horse and provides immunity for three months following two initial injections, four weeks apart. The vaccine significantly reduces clinical signs of strangles and occurrence of lymph node abscesses in horses that are at risk of infection.
Dr. Peter Daels, veterinarian at the Keros Insemination and Embryo Transfer Center in Beselare (Belgium) said: "In our recipient embryo transfer herd, we have used this strangles vaccine on over 500 mares. After a few applications, the vaccine was easy to administer and did not cause any serious side effects. Despite a steady flow of new horses, only eight cases of strangles were noted - all were mild and most were newly acquired horses that had apparently been exposed shortly before vaccination. I believe that the vaccine provided solid protection against the disease, reduced the severity of clinical cases and eliminated the risk of a widespread outbreak in our herd."
Dr. Roberto Ragni-Alunni, Global Technical Manager Equine at Intervet/Schering Plough Animal Health said: "The re-launch of Equilis StrepE in Europe is an important milestone in our efforts to fully meet the needs of our customers in the equine industry. We continue to work in a very intense and comprehensive way to ensure adequate supply of our equine vaccine range".
A research project funded by equine charity The Horse Trust has found that lameness is the most common reason for euthanasing a geriatric horse.
According to the charity, this research is the first in the UK to provide data on the causes of death in geriatric horses. Although post-mortem studies have provided some data regarding causes of death, "old age" was previously reported as a common reason for the euthanasia of adult horses.
The research was carried out by Joanne Ireland at the University of Liverpool and led by Dr Gina Pinchbeck. Ireland surveyed horse owners living in the North-West and Midlands areas of England and North Wales who have a horse aged 15 years or older. 918 owners of geriatric horses were followed in a cohort study and 118 mortalities were reported during the 18 month follow-up period, of which 111 were euthanased.
The researchers found that 24% of horses were euthanased due to lameness; an additional 12% were euthanased due to laminitis - a common cause of lameness. After lameness, colic was the next most common cause of euthanasia, with 21% of owners citing this as the main reason.
In an earlier stage of the project, the researchers had found that half the geriatric horses surveyed suffered from lameness, but only 24% of owners reported the problem.
Dr Pinchbeck said: "Although lameness is common in older horses, this is the first study to quantify its contribution to their mortality.
"Owners are often missing the early signs of lameness in their horse, which means the condition isn't being managed and may deteriorate faster."
Dr Pinchbeck said it would be useful to carry out further research into lameness in geriatric horses to find out the main causes of lameness and how these may be prevented or treated.
The research team also found that half of the horses euthanased were suffering from concurrent health problems and these influenced the owner's decision to euthanase in 43% of cases. The most frequently reported additional health problems were musculoskeletal problems, such as arthritis.
The mortality rate among the horses surveyed was 11 per 100 horse-years at risk, meaning that if 100 geriatric horses were followed for a year, an average of 11 would die. The mortality rate for horses over 30 years of age was over five times the rate than in horses aged 15 - 19 years.
Jeanette Allen, Chief Executive of The Horse Trust, said the data provided by this research is likely to provide useful information for both horse owners and vets to enable them to improve the welfare of older horses. She said: "As there are a significant number of geriatric horses in the UK, it is vital that we understand more about the health problems that affect them. We hope that more owners of older horses will give their horse an annual health-check to enable the horse to have a longer, healthier life."
The research was published in the September 2011 issue of Preventive Veterinary Medicine.
Horiba Medical has announced it is the official exclusive UK distributor of the fully automated Vet abc Plus+ veterinary haematology analyser from scil animal care company GmbH, Germany.
According to the company, the compact Vet abc Plus+ provides a complete blood count (CBC), including 4-part white blood cell (WBC) differential, from only 10 µl of EDTA whole blood, in only 60 seconds.
The Vet abc Plus+ provides pre-installed settings to analyse samples from dogs, cats, horses, rabbits, mice, rats, cattle, pigs and sheep. For dogs, cats and horses, the Vet abc Plus+ provides a 4-part WBC differential blood count, including a differentiation of the leucocytes to identify lymphocytes, monocytes, granulocytes and eosinophils. Results are available in 60 seconds on screen or can be automatically printed out and transferred to the practice information system or clinical notes. For ease-of-use, the Vet abc Plus+ also incorporates a self-contained reagent and waste system which provides a clean operation whilst being easy to replenish.
Borne from an existing manufacturing partnership, scil and HORIBA Medical already have over 6000 veterinary haematology analysers placed globally. Horiba says the new UK distribution agreement enables UK veterinary professionals to not only procure the Vet abc Plus+ analyser, but also receive expert service and support directly from the manufacturer HORIBA Medical and its team of UK specialists.
For more information, visit: www.horiba.com/uk/medical
The traditional method for detecting equine lameness is subjective, using expert visual evaluation of gait to identify the presence or absence and degree of asymmetries. The lame horse is described as having a disorder, defect or loss of function and this clinical diagnosis has associated welfare implications if the horse is still asked to perform.
The article explains how advanced computer technology is starting to change all this. Optic motion capture or the use of inertial measurement units (IMUs) is now enabling the detailed study and quantification of the horse’s gait; objective assessment against preset thresholds. The paper points out that while these digital systems can overcome the temporal and spatial limitations of the human eye they simply rely on one or a number of set gait parameters to decide about lameness and this can present obstacles.
Thresholds are forcibly based on a limited reference population, which doesn’t adequately reflect the millions of horses in the world. The individual environmental and mental conditions for each horse and its day-to-day gait variations are also not accounted for. On this basis to use the term ‘lame’ because a horse demonstrates a subtle gait alteration, causing it to fall below the threshold, could be inappropriate, particularly as it may not affect the horse’s welfare in any way.
Professor Celia Marr, Editor of the Equine Veterinary Journal said: "An important first step is for researchers and clinicians to start to discriminate clearly between 'asymmetry' and 'lameness' and not to use these as interchangeable terms when interpreting gait analysis data. Asymmetry is often, but not always, a hallmark of lameness, but is not a clinical term, whereas lameness is."
The University of Liverpool’s Philip Leverhulme Equine Hospital has installed a standing equine MRI scanner from Hallmarq Veterinary Imaging.
HRH The Princess Royal has opened the Animal Health Trust's new cancer treatment and research facility in Suffolk.
The facility has been purpose-built to treat horses, dogs and cats with cancer. It will also assist in furthering understanding of the disease in animals.
Peter Webbon, Chief Executive of the AHT, said: "2012 marks 70 years of the AHT fighting disease and injury in animals, and the addition of the Cancer Centre is a landmark achievement in our history. We believe this is the first facility of its kind in Europe, purpose-built to treat horses, dogs and cats with cancer. We now have a short commissioning process to undertake but anticipate welcoming the first patients through the doors in early 2013."
The Kennel Club Cancer Centre at the AHT houses a linear accelerator (pictured right) and brachytherapy machine used in radiotherapy treatment, along with a 16-slice CT scanner to aid radiotherapy planning.
The new facility complements the AHT's existing cancer treatment options of surgery and chemotherapy meaning the Suffolk-based charity will be able to offer each and every patient the very best options for their specific case, whatever the diagnosis. With one in four dogs and one in six cats developing cancer at some time in their life the new centre will help many more animals fight cancer.
Peter Webbon, added: "It was thanks to a generous donation from the late Tom Scott, a long-term supporter of the AHT, that we were able to start this development. His donation, along with that from many other AHT supporters, and an interest-free loan of £1.5 million from the Kennel Club has meant this ambitious project has come to fruition so quickly."
It has taken just over a year to build the Cancer Centre which contains more than 2,600 tonnes of concrete and has eight-feet wide solid concrete walls.
On opening the facility, HRH The Princess Royal, President of the AHT, said: "This Cancer Centre is an exciting development at the AHT and will make a real difference for animals with cancer, here and now. It will improve the chances, for many animals, of beating this pernicious disease.
"Countless other horses, dogs and cats across the world with cancer, who will never be seen by an AHT clinician, will also benefit from knowledge gained from research in The Kennel Club Cancer Centre at the AHT."
The AHT has a strong history in cancer research and the Kennel Club Cancer Centre will enhance the charity's well established cancer research programme. Knowledge gained through the treatment of animals in the facility will contribute to the study of cancers, their causes, early diagnosis and treatment, and ultimately hopefully the prevention of some forms of the disease.
Steve Dean, Kennel Club Chairman, said: "I am very proud to be here today to celebrate the opening of the Kennel Club Cancer Centre. Thanks to the expertise available here at the Animal Health Trust, the Cancer Centre will provide advanced techniques for the diagnosis and treatment of cancer, to the benefit of many animals. It is exciting to consider how synergy between the Kennel Club Cancer Centre and the Kennel Club Genetics Centre can help to further the understanding of the inheritance factors that influence the development of cancer."
The BEVA Trust is the Association’s philanthropic arm and in 2015 members decided that it should provide support for voluntary projects to help improve knowledge and welfare.
Since then volunteers have been rolling up their sleeves to help out with castration and welfare clinics in the UK and veterinary training schemes around the world.
Over the past 12 months a total of 42 vets and vet nurses have volunteered their time at seven BHS Education and Welfare Clinics throughout the UK.
They have helped microchip, passport, vaccinate and castrate horses recognised by Welfare Officers as needing help.
So far 598 horses and ponies have received passports and 302 been castrated.
The Trust has seen a further ten volunteers travel across the globe, working on projects in Cambodia, the Gambia, Honduras, Kiev, Nicaragua and the Ukraine.
BEVA President Vicki Nicholls said: "We thank all of the volunteers that make our Trust such a success, with special mention to Luke Edwards from the University of Liverpool and Alice Horne from Ddole Road Veterinary Clinic who have both volunteered at four clinics. We must also remember the good work of our industrious BEVA Council members and our excellent speakers at Congress this September, who are all volunteers."
For further information on BEVA Trust volunteer projects email lara@beva.org.uk to be added to the BEVA Trust mailing list.
The British Equine Veterinary Association (BEVA) has launched two guides to help veterinary professionals and their clients negotiate the complexities of equine insurance.
BEVA highlights that with up to 40% of horses becoming ill or injured in any one year and 25% of insured horses having a claim in any one year, vet fees insurance is a sensible way for horse owners to budget for unexpected healthcare costs.
The Veterinary Surgeon's guide to riding and sport horse insurance provides general guidelines to help vets understand the requirements and issues relating to equine insurance. It explains the three main types of insurance cover available: veterinary fees, death and permanent loss of use, as well as insurance recommendations for pre-purchase and pre-insurance vetting. The final section contains a jargon-busting guide to commonly used insurance terminology.
Complementing the vet guide is The BEVA leisure and sports horse Insurance Guide for horse owners, a handout for clients about to embark on taking out insurance. It covers the frequently asked questions relating to vets fees and death, including when and how to insure, the importance of pre-purchase vetting, exclusions and permanent loss of use.
Andrew Harrison, Junior Vice President of BEVA, said: "Whether a vet or a horse owner, understanding equine insurance can be intimidating for the best of us. The new guides should make it easier for you and your clients to understand the finer points of policies, premiums and claim protocols."
The guides can be downloaded from the BEVA website via the following links:
For additional information visit www.beva.org.uk